| Vol. 13.05 – 12 February, 2021 |
| |
|
|
| Researchers used muscle injury models in zebrafish to systematically capture the interactions between satellite cells and the innate immune system after injury, in real time, throughout the repair process. [Nature] |
| |
|
|
PUBLICATIONSRanked by the impact factor of the journal |
|
|
|
| Scientists discovered that brain tumor cells had a particularly high demand for oxygen, which affected γδ T cell-mediated antitumor immune responses but not those of conventional T cells. [Nature Immunology] |
|
|
|
| Investigators demonstrated that α-amanitin–conjugated trastuzumab potentiated the human epidermal growth factor receptor 2 (HER2)-targeted therapy and exhibited superior efficacy in treating HER2-low breast cancer with 17p loss. [Science Translational Medicine] |
|
|
|
| Scientists describe that postsynaptic dendritic cells switch their transcriptomic signature, correlating with epigenomic changes including DNA accessibility and histone methylation. [Science Advances] |
|
|
|
| In a macrophage-inhibited mouse model, sulfated chitosan efficiently helped to recover the endogenous levels of vascular endothelial growth factor (VEGF) and the number of CD31hiEmcnhi vessels in ischemia. [Science Advances] |
|
|
|
| Researchers demonstrated that IL-21 could be targeted to tumor-reactive T cells by fusion of IL-21 to anti-PD-1 antibody. [Nature Communications] |
|
|
|
| Investigators characterized the transcriptional and epigenetic landscape of self-reactive CD8+ T cells in a mouse model of protracted central nervous system autoimmunity and compared it to populations of central nervous (CNS) system-resident memory CD8+ T cells emerging from acute viral infection. [Nature Communications] |
|
|
|
| The authors combined the agonistic activity of IgG monoclonal antibodies and IgA Fc receptor targeting in a therapeutic bispecific antibody format. [Journal of Clinical Investigation] |
|
|
|
| Using fate-mapping mice, researchers reported that prostaglandin I2 signaling prevented Treg reprogramming toward a pathogenic phenotype. [Journal of Clinical Investigation] |
|
|
|
| Using single-cell RNA-seq, cell mass spectrometry, flow cytometry, and functional analysis, investigators characterized the heterogeneity of polymorphonuclear neutrophils in cancer. [Journal of Experimental Medicine] |
|
|
|
| The authors studied CD4+ T cells in a mouse model with regulatable antigen presentation. [Cell Reports] |
|
|
|
| Scientists report that smectite, a type of mineral clay and established anti-diarrhea drug, promoted expansion of probiotics in the murine gut and subsequently elicited anti-tumor immune responses. [Cell Reports] |
|
|
|
|
| The authors describe the recent discovery of atypical modulators and partners of RHO GTPases, which bring an additional layer of regulation and plasticity to the control of RHO GTPase activities in the immune system. [Nature Reviews Immunology] |
|
|
|
| Investigators discuss the multifaceted roles of tumor‐associated macrophages and neutrophils, focusing on factors that subvert tissue immune homeostasis and offer therapeutic opportunities for tumor microenvironment reprogramming. [Immunological Reviews] |
|
|
|
| Scientists discuss the scenarios that trigger CD8 memory T cells bystander activation including acute and chronic infections that are either systemic or localized. [Journal of Immunology] |
|
|
|
|
| Exscientia announced its collaboration with the Alzheimer’s Research UK University of Oxford Drug Discovery Institute to develop medicines targeting neuroinflammation for the treatment of Alzheimer’s disease. [Exscientia] |
|
|
|
| Apollomics, Inc., announced an exclusive license agreement for the development and commercialization of TYG100 in Mainland China, Hong Kong, Macau and Taiwan, also known as Greater China, and South Africa. [Apollomics, Inc.] |
|
|
|
|
|
|
|
| Augusta University – Augusta, Georgia, United States |
|
|
|
| University of Washington – Seattle, Washington, United States |
|
|
|
| Karolinska Institutet – Stockholm, Sweden |
|
|
|
| Oslo University Hospital – Oslo, Norway |
|
|
|
| Oklahoma Medical Research Foundation – Oklahoma City, Oklahoma, United States |
|
|
|
|